Semaglutide Slows Biological Aging 9% in HIV Trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Semaglutide slowed biological aging by 9% on the DunedinPACE epigenetic clock in a randomized, placebo-controlled trial of 108 adults with HIV-associated lipohypertrophy, per a Nature Communications study from UC San Diego — the first such evidence in humans.
- UC San Diego researchers measured slower aging across multiple epigenetic clocks tied to inflammation and the health of blood, brain, heart, kidneys, liver, and metabolism, with the PCGrimAge clock showing reduced all-cause mortality risk.
- Michael Corley, the study's first author and a UC San Diego associate professor, said GLP-1 drugs may slow aging by reducing inflammation and visceral/ectopic fat, and possibly by reprogramming cells in different organs.
- A related npj Aging pilot study of people with HIV and fatty liver disease found 42% of participants showed slowed biological aging, 34% had slower mortality-risk aging, and nearly 49% showed longer telomeres after 24 weeks of semaglutide.
- Researchers cautioned that semaglutide is not an anti-aging drug, with Corley stating "we are not saying that semaglutide reverses aging or makes people younger" and calling for much larger trials to confirm the results.
- The Stein Institute for Research on Aging plans to use the findings to develop personalized "aging dashboards" based on epigenetic clocks to help clinicians monitor biological aging and design individualized treatments.
Why it matters: For the millions already taking GLP-1 drugs for weight loss and diabetes, these findings raise the prospect of aging-related benefits beyond approved uses — though researchers stress the 9% slowing was measured in just 108 HIV patients and requires much larger trials. Corley serves as a scientific advisor for TruDiagnostic, an epigenetic-testing company positioned to monetize the resulting "aging dashboards."
Ask SkimNews
